Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 83,958	$ 34,915
Marketable securities	19,970	61,146
Due from related parties	2,047	2,003
Prepaid expenses and other current assets (including amounts with related parties)	7,756	13,649
Total current assets	113,731	111,713
Marketable securities, noncurrent	822	950
Property, plant and equipment, net	89,023	72,541
Non-marketable equity investment	0	7,849
Intangible asset, net	1,445	1,463
Convertible note receivable	6,253	6,129
Operating lease right-of-use assets, net (including amounts with related parties)	28,230	18,138
Other assets (including amounts with related parties)	6,797	2,598
Total assets	246,301	221,381
Current liabilities:
Accounts payable	19,153	11,510
Accrued expenses and other liabilities	36,134	36,771
Due to related parties	16,711	14,838
Operating lease liabilities (including amounts with related parties)	2,430	5,015
Total current liabilities	74,428	68,134
Related-party notes payable	300,252	254,353
Operating lease liabilities, less current portion (including amounts with related parties)	29,116	16,179
Deferred income tax liability	170	170
Other liabilities	920	1,035
Total liabilities	404,886	339,871
Commitments and contingencies (Note 7)	0	0
Stockholders’ deficit:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 390,347,740 and 382,243,142 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively; excluding treasury stock, 163,800 shares outstanding as of June 30, 2021 and December 31, 2020, respectively	39	38
Additional paid-in capital	1,625,018	1,495,163
Accumulated deficit	(1,783,033)	(1,615,131)
Accumulated other comprehensive income	37	122
Total ImmunityBio stockholders’ deficit	(157,939)	(119,808)
Noncontrolling interests	(646)	1,318
Total stockholders’ deficit	(158,585)	(118,490)
Total liabilities and stockholders’ deficit	$ 246,301	$ 221,381